Cellares said it has manufactured and enabled dosing of Cabaletta Bio’s investigational autologous CAR T therapy rese-cel (resecabtagene autoleucel) into the first two patients. The cells were produced using Cellares’ automated Cell Shuttle platform, and the initial infusions met release criteria. Cabaletta and Cellares framed the dosing milestone as evidence that scalable autologous CAR-T manufacturing can be executed with less manual labor and reduced capital intensity, addressing long-standing bottlenecks that limit patient access. The therapy is engineered with a fully human CD19 binder and a 4-1BB co-stimulatory domain, designed for transient and deep CD19-positive cell depletion. The update is clinically relevant because rese-cel is positioned for autoimmune indications, where durable responses without chronic therapy could expand the CAR-T addressable market beyond oncology while increasing demand for reproducible manufacturing at scale.